NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.

Novel targeted therapies (small molecule inhibitors, antibody-drug conjugates, and CD19-directed therapies) have changed the treatment landscape of relapsed/refractory B-cell lymphomas. Bruton's tyrosine kinase (BTK) inhibitors continue to evolve in the management of mantle cell lymphoma (MCL), in both the relapsed/refractory and the frontline setting. Anti-CD19 CAR T-cell therapies are now effective and approved treatment options for relapsed/refractory follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and MCL. Bispecific T-cell engagers represent a novel immunotherapeutic approach for relapsed FL and DLBCL after multiple lines of therapies, including prior CAR T-cell therapy. These NCCN Guideline Insights highlight the significant updates to the NCCN Guidelines for B-Cell Lymphomas for the treatment of FL, DLBCL, and MCL.

[1]  A. Salar,et al.  Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study. , 2023, Journal of Clinical Oncology.

[2]  W. Klapper,et al.  Long‐term outcome in patients with mantle cell lymphoma following high‐dose therapy and autologous stem cell transplantation , 2023, European journal of haematology.

[3]  I. Flinn,et al.  Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma , 2023, Blood.

[4]  T. Olson,et al.  How I treat cytopenias after CAR T-cell therapy , 2023, Blood.

[5]  T. Phillips,et al.  Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  F. Hernandez-Ilizaliturri,et al.  Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study , 2022, Blood.

[7]  P. Ganly,et al.  Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. , 2022, The New England journal of medicine.

[8]  C. Carlo-Stella,et al.  Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. , 2022, The New England journal of medicine.

[9]  W. Klapper,et al.  High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  L. Sehn,et al.  Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study , 2022, Blood.

[11]  A. Alencar,et al.  Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study , 2022, Blood.

[12]  E. Giné,et al.  Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network , 2022, Blood.

[13]  J. Burke,et al.  Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study. , 2022, The Lancet. Haematology.

[14]  E. Giné,et al.  Real‐world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR‐2 retrospective chart review study , 2022, British journal of haematology.

[15]  P. Zinzani,et al.  MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study. , 2022, Clinical lymphoma, myeloma & leukemia.

[16]  L. Sehn,et al.  Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. , 2022, The Lancet. Oncology.

[17]  P. Riedell,et al.  Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. , 2022, The Lancet. Oncology.

[18]  S. Opat,et al.  Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre , 2022, Internal medicine journal.

[19]  A. Rosenwald,et al.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms , 2022, Leukemia.

[20]  R. Houot,et al.  Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  I. Flinn,et al.  Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. , 2022, The New England journal of medicine.

[22]  L. Staudt,et al.  The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee. , 2022, Blood.

[23]  R. Pazdur,et al.  The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint. , 2022, The Lancet. Oncology.

[24]  M. Kersten,et al.  Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial , 2021, Nature Medicine.

[25]  M. Kersten,et al.  Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. , 2021, The New England journal of medicine.

[26]  S. de Vos,et al.  Long-Term Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL) , 2021, Blood.

[27]  M. Kersten,et al.  Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. , 2021, The Lancet. Oncology.

[28]  Michael L. Wang,et al.  American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma , 2021, Transplantation and cellular therapy.

[29]  W. Klapper,et al.  Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. , 2021, The Lancet. Haematology.

[30]  J. Byrd,et al.  Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Michael L. Wang,et al.  Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. , 2021, Blood advances.

[32]  J. Radford,et al.  Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. , 2021, The Lancet. Oncology.

[33]  J. Burke,et al.  Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  G. Follows,et al.  Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real‐world analysis of outcomes in 211 patients , 2021, British journal of haematology.

[35]  Michael L. Wang,et al.  Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib , 2021, American journal of hematology.

[36]  K. Ahn,et al.  Is Autologous Transplant in Relapsed DLBCL Patients Achieving Only a PET+ PR Appropriate in the CAR-T cell Era? , 2020, Blood.

[37]  G. Salles,et al.  Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. , 2020, The Lancet. Oncology.

[38]  Michael L. Wang,et al.  Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study , 2020, The Lancet.

[39]  Z. Zemanová,et al.  A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma , 2020, British journal of haematology.

[40]  Sourav K. Mishra,et al.  Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. , 2020, The Lancet. Haematology.

[41]  G. Salles,et al.  Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. , 2020, The Lancet. Oncology.

[42]  Michael L. Wang,et al.  Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) ‐ outcomes and mutation profile from venetoclax resistant MCL patients , 2020, American journal of hematology.

[43]  L. Medeiros,et al.  Outcomes in patients with aggressive B‐cell non‐Hodgkin lymphoma after intensive frontline treatment failure , 2020, Cancer.

[44]  G. Lenz,et al.  Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study , 2019, American journal of hematology.

[45]  W. Klapper,et al.  Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  L. Sehn,et al.  Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Michael L. Wang,et al.  Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma , 2019, Leukemia.

[48]  D. Rossi,et al.  KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study , 2019, Haematologica.

[49]  D. Maloney,et al.  Outcomes of patients with large B‐cell lymphomas and progressive disease following CD19‐specific CAR T‐cell therapy , 2019, American journal of hematology.

[50]  J. Byrd,et al.  Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. , 2019, Blood advances.

[51]  S. Grupp,et al.  ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[52]  I. Flinn,et al.  DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  W. Klapper,et al.  Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge! , 2018, Blood.

[54]  D. Šálek,et al.  Rituximab maintenance significantly prolongs progression‐free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation , 2018, American journal of hematology.

[55]  M. Dyer,et al.  Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy , 2018, Haematologica.

[56]  Michael L. Wang,et al.  Four‐year follow‐up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL) , 2018, British journal of haematology.

[57]  J. Goldberg,et al.  Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study , 2018, Leukemia.

[58]  Michael L. Wang,et al.  Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004) , 2017, Journal of Hematology & Oncology.

[59]  J. W. Hansen,et al.  TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. , 2017, Blood.

[60]  J. Cerhan,et al.  Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. , 2017, Blood.

[61]  R. Houot,et al.  Rituximab after Autologous Stem‐Cell Transplantation in Mantle‐Cell Lymphoma , 2017, The New England journal of medicine.

[62]  G. Salles,et al.  Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. , 2017, Blood.

[63]  R. Advani,et al.  Postibrutinib outcomes in patients with mantle cell lymphoma. , 2016, Blood.

[64]  S. Smith,et al.  Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[65]  Michael L. Wang,et al.  Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. , 2015, Blood.

[66]  G. Salles,et al.  PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. , 2014, The New England journal of medicine.

[67]  Michael L. Wang,et al.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. , 2013, The New England journal of medicine.

[68]  E. Giné,et al.  Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. , 2012, Cancer research.

[69]  P. Mclaughlin,et al.  Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. , 2012, The Lancet. Oncology.

[70]  M. Pfreundschuh,et al.  High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[71]  R. Lai,et al.  Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis , 2011, Haematologica.

[72]  A. Rosenwald,et al.  Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. , 2010, Cancer research.

[73]  A. Hagenbeek,et al.  High‐dose Ara‐C and beam with autograft rescue in R‐CHOP responsive mantle cell lymphoma patients , 2009, British journal of haematology.

[74]  D. Maloney,et al.  Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma , 2008, Leukemia & lymphoma.

[75]  G. Salles,et al.  Chemotherapy with rituximab followed by high‐dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma , 2005, Cancer.

[76]  E. Hoster,et al.  Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. , 2004, Blood.

[77]  A. López-Guillermo,et al.  Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[78]  J. Armitage,et al.  Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  A. Hagenbeek,et al.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.

[80]  P. Hwu,et al.  Chimeric antigen receptor T-cell therapy — assessment and management of toxicities , 2018, Nature Reviews Clinical Oncology.

[81]  N. Schmitz,et al.  Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study , 2016, Bone Marrow Transplantation.

[82]  A. F. Sevilla,et al.  High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[83]  C. Turtle,et al.  Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission , 2022 .